ClinConnect ClinConnect Logo
Search / Trial NCT03092089

Sonothrombolysis in Patients With STEMI

Launched by HARALD BECHER · Mar 21, 2017

Trial Information

Current as of July 22, 2025

Completed

Keywords

Sonothrombolysis, Stemi, Ppci, Microbubbles

ClinConnect Summary

This is a prospective, single center, single-arm study that examines pre-procedural sonothrombolysis as an adjuvant to contemporary therapy in patients with ST-segment elevation myocardial infarction receiving PPCI.This study is to examine what effect adding emergent diagnostic ultrasound (DUS) guided high mechanical index (HMI) impulses (sonothrombolysis), applied both before and after primary percutaneous coronary intervention (PPCI) during an intravenous commercially available microbubble infusion (Definity), have on spontaneous reperfusion (i.e. pre PCI coronary artery patency rates), m...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients presenting with STEMI within 6 hours of symptom onset and:
  • 1. Are expected to receive reperfusion therapy with primary PCI
  • 2. Have a high-risk STEMI ECG defined as:
  • ≥2mm ST-segment elevation in 2 anterior or lateral leads; or
  • ≥2 mm ST-segment elevation in 2 inferior leads coupled with ST segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥4mm
  • 3. Age ≥30 years.
  • 4. Adequate apical and/or parasternal images by echocardiography
  • Exclusion Criteria:
  • 1. Isolated inferior STEMI without anterior ST-segment depression
  • 2. Previous coronary bypass surgery
  • 3. Cardiogenic shock
  • 4. Known or suspected hypersensitivity to ultrasound contrast agent used for the study
  • 5. Life expectancy of less than two months or terminally ill.
  • 6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin
  • 7. Known large right to left intracardiac shunts.

About Harald Becher

Harald Becher is a distinguished clinical trial sponsor renowned for his commitment to advancing medical research and innovation. With extensive experience in the pharmaceutical and biotechnology sectors, he focuses on developing novel therapies that address unmet medical needs. Under his leadership, the organization emphasizes rigorous study design, ethical standards, and patient safety, fostering collaborations with academic institutions and industry partners. By leveraging cutting-edge technologies and a patient-centric approach, Harald Becher is dedicated to delivering transformative solutions that enhance healthcare outcomes.

Locations

Edmonton, Alberta, Canada

Patients applied

0 patients applied

Trial Officials

Harald Becher

Principal Investigator

University of Alberta

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials